Catalent (CTLT) Stock Price & Analysis

CTLT$63.480.00 0.00%
Drug Manufacturers - Specialty & GenericLarge Cap
Compare
Market cap$11.52BEnterprise value$16.22BRevenue (TTM)$4.42BMarket positionTop 25%

Score

35
Bearish
Value
43
Quality
20
Growth
42

AI Analysis

Snapshot

Catalent doesn’t screen as a clean setup today — Stocklytics 35/100 leaves more to prove. Under the hood: revenue compounding ~4% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

43
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

42
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

20
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Catalent, Inc. (CTLT) last printed $63.48. Equity value is $11.52B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2015201620172018201920202021202220232024
$1.83B$1.85B$2.08B$2.46B$2.52B$3.09B$4B$4.83B$4.28B$4.38B

About

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

Catalent (CTLT) Stock Price & Analysis

CTLT price $63.48 0.00 0.00%

Ticker
CTLT
Price
$63.48
Change
0.00 0.00%
Market cap
$11.52B
Forward P/E
26.56
Dividend yield
0.00%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
35
Value
43
Quality
20
Growth
42

Stocklytics score rationale: value 43, quality 20, growth 42.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener